Michael Kragh Selected Research

futuximab

1/2020	Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation.
1/2020	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
7/2018	Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
4/2018	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
1/2016	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
6/2015	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
12/2013	Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.
10/2013	Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
9/2011	Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
1/2010	Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Kragh Research Topics

Disease

32	Neoplasms (Cancer) 01/2020 - 02/2002
8	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 10/2013
3	Stomach Neoplasms (Stomach Cancer) 11/2019 - 01/2018
3	Neoplasm Metastasis (Metastasis) 02/2016 - 07/2005
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 12/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016 - 10/2013
2	Renal Cell Carcinoma (Grawitz Tumor) 03/2008 - 09/2007
1	Body Weight (Weight, Body) 01/2020
1	Residual Neoplasm 01/2020
1	Triple Negative Breast Neoplasms 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 07/2018
1	Carcinogenesis 02/2016
1	Squamous Cell Carcinoma of Head and Neck 01/2016
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2016
1	Breast Neoplasms (Breast Cancer) 03/2015
1	Lung Neoplasms (Lung Cancer) 12/2013
1	Melanoma (Melanoma, Malignant) 03/2008
1	Experimental Melanoma 09/2007
1	Hemorrhage 10/2005
1	Embolism (Embolus) 10/2005
1	Foreign-Body Reaction 02/2003
1	Carcinoma (Carcinomatosis) 05/2002
1	Glioma (Gliomas) 02/2002

Drug/Important Bio-Agent (IBA)

13	ErbB Receptors (EGF Receptor)IBA 01/2020 - 01/2010
10	futuximabIBA 01/2020 - 01/2010
7	AntibodiesIBA 01/2020 - 01/2010
6	LigandsIBA 01/2020 - 01/2010
6	Monoclonal AntibodiesIBA 04/2018 - 09/2007
6	Cetuximab (Erbitux)FDA Link 01/2016 - 10/2013
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 09/2007
4	EpitopesIBA 12/2017 - 01/2010
3	Trastuzumab (Herceptin)FDA Link 11/2019 - 03/2015
3	Pharmaceutical PreparationsIBA 01/2018 - 07/2005
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 01/2016
3	Panitumumab (Vectibix)FDA Link 01/2016 - 06/2015
2	emibetuzumabIBA 01/2018 - 10/2017
2	interleukin-21 (interleukin 21)IBA 03/2008 - 09/2007
2	CytokinesIBA 03/2008 - 09/2007
2	CoagulantsIBA 10/2005 - 07/2005
2	Heparin (Liquaemin)FDA LinkGeneric 10/2005 - 07/2005
1	RNA (Ribonucleic Acid)IBA 01/2020
1	human ERBB2 proteinIBA 01/2020
1	AlbuminsIBA 01/2020
1	BuffersIBA 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	Cell Surface ReceptorsIBA 01/2020
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2019
1	epidermal growth factor receptor VIIIIBA 07/2018
1	Circulating Tumor DNAIBA 04/2018
1	Neutralizing AntibodiesIBA 11/2017
1	Neuregulin-1 (Neuregulin 1)IBA 11/2017
1	Messenger RNA (mRNA)IBA 11/2017
1	Immunoglobulin G (IgG)IBA 10/2017
1	pertuzumabIBA 03/2015
1	Caspase 3 (Caspase-3)IBA 10/2013
1	InterleukinsIBA 09/2007
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 07/2005
1	Tinzaparin (Innohep)FDA Link 07/2005
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 02/2003
1	Prednisolone (Predate)FDA LinkGeneric 02/2003
1	Indomethacin (Indometacin)FDA LinkGeneric 02/2003
1	flavone acetic acidIBA 05/2002
1	Hydralazine (Apresoline)FDA LinkGeneric 05/2002
1	Niacinamide (Nicotinamide)FDA LinkGeneric 05/2002
1	vadimezanIBA 05/2002
1	fosbretabulin (combretastatin A4)IBA 05/2002
1	Thrombospondin 1IBA 02/2002
1	Complementary DNA (cDNA)IBA 02/2002
1	ThrombospondinsIBA 02/2002

Therapy/Procedure

17	Therapeutics 01/2020 - 02/2002
3	Aftercare (After-Treatment) 01/2020 - 05/2002
2	Radiotherapy 02/2016 - 12/2013
2	Lasers (Laser) 05/2002 - 02/2002
1	Immunotherapy 01/2019